{"cik":2075320,"taxonomy":"us-gaap","tag":"EarningsPerShareBasic","label":"Earnings Per Share, Basic","description":"The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.","entityName":"Polaryx Therapeutics, Inc.","units":{"USD/shares":[{"start":"2024-01-01","end":"2024-12-31","val":-0.89,"accn":"0001213900-26-033064","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-24","frame":"CY2024"},{"start":"2025-01-01","end":"2025-03-31","val":-0.11,"accn":"0001213900-26-056973","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-15","frame":"CY2025Q1"},{"start":"2025-01-01","end":"2025-06-30","val":-0.14,"accn":"0001213900-26-089118","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-13"},{"start":"2025-04-01","end":"2025-06-30","val":-0.02,"accn":"0001213900-26-089118","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-13","frame":"CY2025Q2"},{"start":"2025-01-01","end":"2025-12-31","val":-0.2,"accn":"0001213900-26-033064","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-24","frame":"CY2025"},{"start":"2026-01-01","end":"2026-03-31","val":-0.05,"accn":"0001213900-26-056973","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-15","frame":"CY2026Q1"},{"start":"2026-01-01","end":"2026-06-30","val":-0.08,"accn":"0001213900-26-089118","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-13"},{"start":"2026-04-01","end":"2026-06-30","val":-0.03,"accn":"0001213900-26-089118","fy":2026,"fp":"Q2","form":"10-Q","filed":"2026-08-13","frame":"CY2026Q2"}]}}